Dr. Lentzsch on the LINKER-MM1 Study Presented at EHA 2024

Suzanne Lentzsch, MD, PhD, of Columbia University, describes the LINKER-MM1 study on linvoseltamab in patients with relapsed or refractory multiple myeloma (MM) presented at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain.

The investigational bispecific antibody achieved an overall response rate of 71%. Half (50%) of the patients achieved a complete response (CR) or better, and 63% achieved a very good partial response or better. Those who achieved a CR had a higher rate of measurable residual disease negativity.

“That means if the patients responded, their responses were usually very, very deep,” Dr. Lentzsch explained.

As for adverse events, cytokine release syndrome of any grade occurred in around 46% of patients. Of the 75% of patients who experienced an infection, 36% had grade 3 or 4 infection.

“The infection rate decreased with the time of treatment and was handled relatively well with appropriate prophylaxis,” said Dr. Lentzsch.